Newsletter - May 31, 2018
Survey Shows Multivitamins Do Not Reduce Mortality but Does it Matter?
Dietary supplements such as multivitamins are regularly consumed by more than 50% of the population in the US but they may not have much effect on the prolongation of lifespan as shown by a study published this week. A group of nutrition experts conducted a meta-analysis of data from 179 randomized clinical trials conducted over 5 years (2012-2017) selected based on their endpoints and quality of data. Read More
In the Age of Personalized Medicine and Right to Try, Have Big Clinical Trials Become Obsolete?
An opinion piece in the Wall Street Journal this week raises an interesting question: is the era of large Phase 3 clinical trials coming to an end. It is a reasonable argument that when treatments can be customized to patients via personalized therapies, and the benefit of a new drug can be supported by real world patient experience from compassionate use, why do we still need large Phase 3 trials to get FDA approval. Read more
Survey Shows Multivitamins Do Not Reduce Mortality but Does it Matter?
Dietary supplements such as multivitamins are regularly consumed by more than 50% of the population in the US but they may not have much effect on the prolongation of lifespan as shown by a study published this week. A group of nutrition experts conducted a meta-analysis of data from 179 randomized clinical trials conducted over 5 years (2012-2017) selected based on their endpoints and quality of data. Read More
In the Age of Personalized Medicine and Right to Try, Have Big Clinical Trials Become Obsolete?
An opinion piece in the Wall Street Journal this week raises an interesting question: is the era of large Phase 3 clinical trials coming to an end. It is a reasonable argument that when treatments can be customized to patients via personalized therapies, and the benefit of a new drug can be supported by real world patient experience from compassionate use, why do we still need large Phase 3 trials to get FDA approval. Read more
